KalVista (KALV) announced that the European Commission and Swiss Agency for Therapeutic Products, Swissmedic, have approved Ekterly, a novel, oral plasma kallikrein inhibitor, for the symptomatic treatment of acute attacks of hereditary angioedema in adults and adolescents aged 12 years and older.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- Strong Initial Sales and Medical Endorsement Drive Buy Rating for KalVista Pharmaceuticals’ Ekterly
- Promising Launch of Ekterly Boosts KalVista Pharmaceuticals’ Market Potential
- KalVista price target raised to $28 from $27 at Citizens JMP
- KalVista Pharmaceuticals Reports Strong Start for EKTERLY Launch
- Promising Market Penetration and Growth Potential for KalVista Pharmaceuticals’ Ekterly